Author

Kyung‐Mi Kee

Observed name: Kyung-Mi Kee

Institutions: Eulji University, Eulji University Uijeongbu Eulji Medical Center

Observed institutions: Eulji University, Eulji University Uijeongbu Eulji Medical Center, Catholic University of Korea

ORCID: 0000-0002-2094-6667

Observed ORCID: 0000-0002-2094-6667

OpenAlex ID: A5033511580

Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemia

2023 · Ji Eun Shin, Soo-Hyun Kim, et al. · Molecular Cancer · 28

Baseline BCR-ABL1 transcript type of e13a2 and large spleen size are predictors of poor long-term outcomes in chronic phase chronic myeloid leukemia patients who failed to achieve an early molecular response after 3 months of imatinib therapy

2017 · Sung-Eun Lee, Soo-Young Choi, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 10

Compound mutations involving T315I and P-loop mutations are the major components of multiple mutations detected in tyrosine kinase inhibitor resistant chronic myeloid leukemia

2018 · Ki-Hoon Kang, Soo-Hyun Kim, et al. · Leukemia Research · 8

Reciprocal interactions among Cobll1, PACSIN2, and SH3BP1 regulate drug resistance in chronic myeloid leukemia

2022 · Kibeom Park, Hee‐Seop Yoo, et al. · Cancer Medicine · 7

Comprehensive analyses of safety and efficacy toward individualizing imatinib dosage in patients with chronic myeloid leukemia

2019 · Hyejin Shin, Soo Young Choi, et al. · International Journal of Hematology · 7

BCR ‐ ABL 1 transcript levels at 4 weeks have prognostic significance for time‐specific responses and for predicting survival in chronic‐phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors

2018 · Hye‐young Song, Hayeon Noh, et al. · Cancer Medicine · 7

A More Rapid Initial Decline of BCR::ABL1 Transcripts and Longer Treatment Duration with Improvement of Treatment-Free Remission Rate after Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

2024 · Sewon Lee, Yeung-Chul Mun, et al. · Blood · 2

Next-generation digital polymerase chain reaction assay for BCR::ABL1 in chronic myeloid leukemia: comprehensive validation for standardized measurable residual disease detection

2026 · Yong-Hwi Kim, Min-Sik Jang, et al. · Blood Research

Predictors of successful tirosine kinase inhibitor discontinuation in chronic myeloid leukemia: Long-term, real-world evidence on the role of faster molecular decline and duration of response

2025 · Sewon Lee, Yeung-Chul Mun, et al. · Blood

Improvement of Treatment-Free Remission Rate Following Discontinuation of BCR::ABL1 Tyrosine Kinase Inhibitors in Chronic Phase, Chronic Myeloid Leukemia

2023 · Sewon Lee, Hongtae Kim, et al. · Blood

Comparison of 3-month cytogenetic and molecular assays for early assessment of long-term clinical impact after BCR-ABL1 tyrosine kinase inhibitor treatment in chronic myeloid leukemia

2021 · Kyung-Mi Kee, Soo-Hyun Kim, et al. · Leukemia Research

Clinical Response Evaluation Toward Individualizing the Starting Dose of Dasatinib in Asian Patients with Chronic Myeloid Leukemia

2020 · Hyejin Shin, Jung-Eun Ha, et al. · Blood

Works count: 12

Citation count: 69

H-index: 6

I10-index: 2